Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2

Vaccine

Volumn 27, Issue 44, 2009, Pages 6154-6159

  Duan, Xuefeng ^a   Yonemitsu, Yoshikazu ^a   Chou, Bin ^a   Yoshida, Kumi ^a   Tanaka, Sakura ^a   Hasegawa, Mamoru ^b   Tetsutani, Kohhei ^a   Ishida, Hidekazu ^a   Himeno, Kunisuke ^a   Hisaeda, Hajime ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b DNAVEC Corporation   (Japan)

Author keywords

Amastigote surface protein 2; Non transmissible Sendai virus; Trypanosoma cruzi

Indexed keywords

AMASTIGOTE SURFACE PROTEIN 2; GAMMA INTERFERON; MEMBRANE PROTEIN; RECOMBINANT SENDAI VIRUS VECTOR; UBIQUITIN; UBIQUITIN AMASTIGOTE SURFACE PROTEIN 2; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENDAI VIRUS; SPLEEN CELL; TRYPANOSOMA CRUZI; VIRUS RECOMBINANT;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CHAGAS DISEASE; FEMALE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; NEURAMINIDASE; PROTOZOAN VACCINES; SENDAI VIRUS; TRYPANOSOMA CRUZI; VACCINES, SYNTHETIC;

EID: 70349783754     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.026     Document Type: Article

References (48)

1. Urbina J.A. Specific treatment of Chagas disease: current status and new developments. Curr Opin Infect Dis 14 6 (2001) 733-741
2. Camandaroba E.L., Reis E.A., Goncalves M.S., Reis M.G., and Andrade S.G. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 36 March-April (2) (2003) 201-209
3. Menezes H. Protective effect of an avirulent (cultivated) strain of Trypanosoma cruzi against experimental infection in mice. Rev Inst Med Trop Sao Paulo 10 January-February (1) (1968) 1-4
4. Basombrio M.A. Trypanosoma cruzi: partial prevention of the natural infection of guinea pigs with a killed parasite vaccine. Exp Parasitol 71 1 (1990) 1-8
5. Pinge-Filho P., Peron J.P., de Moura T.R., Menolli R.A., Graca V.K., Estevao D., et al. Protective immunity against Trypanosoma cruzi provided by oral immunization with Phytomonas serpens: role of nitric oxide. Immunol Lett 96 January (2) (2005) 283-290
6. Wrightsman R.A., Dawson B.D., Fouts D.L., and Manning J.E. Identification of immunodominant epitopes in Trypanosoma cruzi trypomastigote surface antigen-1 protein that mask protective epitopes. J Immunol 153 7 (1994 Oct 1) 3148-3154
7. + TC1 responses. J Immunol 159 December (12) (1997) 6120-6130
8. Costa F., Franchin G., Pereira-Chioccola V.L., Ribeirao M., Schenkman S., and Rodrigues M.M. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16 8 (1998) 768-774
9. Wizel B., Garg N., and Tarleton R.L. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 66 11 (1998) 5073-5081
10. + T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun 69 9 (2001) 5477-5486
11. Garg N., and Tarleton R.L. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70 10 (2002) 5547-5555
12. Katae M., Miyahira Y., Takeda K., Matsuda H., Yagita H., Okumura K., et al. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect Immun 70 9 (2002) 4833-4840
13. Fralish B.H., and Tarleton R.L. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 21 June (21-22) (2003) 3070-3080
14. Dumonteil E., Escobedo-Ortegon J., Reyes-Rodriguez N., Arjona-Torres A., and Ramirez-Sierra M.J. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun 72 1 (2004) 46-53
15. Chou B., Hisaeda H., Shen J., Duan X., Imai T., Tu L., et al. Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein. Microbes Infect 10 3 (2008) 241-250
16. Schnapp A.R., Eickhoff C.S., Sizemore D., Curtiss III R., and Hoft D.R. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun 70 9 (2002) 5065-5074
17. Boscardin S.B., Kinoshita S.S., Fujimura A.E., and Rodrigues M.M. Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect Immun 71 5 (2003) 2744-2757
18. Vasconcelos J.R., Hiyane M.I., Marinho C.R., Claser C., Machado A.M., Gazzinelli R.T., et al. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 15 9 (2004) 878-886
19. Fontanella G.H., De Vusser K., Laroy W., Daurelio L., Nocito A.L., Revelli S., et al. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate. Vaccine 26 May (19) (2008) 2322-2334
20. Cazorla S.I., Frank F.M., Becker P.D., Corral R.S., Guzman C.A., and Malchiodi E.L. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. Vaccine 26 April (16) (2008) 1999-2009
21. Rocha C.D., Caetano B.C., Machado A.V., and Bruna-Romero O. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7 2 (2004) 83-94
22. Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24 April (15) (2006) 3026-3034
23. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Lang T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24 May (22) (2006) 4709-4715
24. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10 11 (2004) 1240-1244
25. Greenough T.C., Cunningham C.K., Muresan P., McManus M., Persaud D., Fenton T., et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 26 December (52) (2008) 6883-6893
26. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., Ueda Y., et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 74 14 (2000) 6564-6569
27. Zhang M., Obata C., Hisaeda H., Ishii K., Murata S., Chiba T., et al. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte. Gene Ther 12 13 (2005) 1049-1057
28. + T cells. Int Immunol 18 5 (2006) 679-687
29. Ishii K., Hisaeda H., Duan X., Imai T., Sakai T., Fehling H.J., et al. The involvement of immunoproteasomes in induction of MHC class I-restricted immunity targeting Toxoplasma SAG1. Microbes Infect 8 4 (2006) 1045-1053
30. Hirata T., Iida A., Shiraki-Iida T., Kitazato K., Kato A., Nagai Y., et al. An improved method for recovery of F-defective Sendai virus expressing foreign genes from cloned cDNA. J Virol Methods 104 2 (2002) 125-133
31. Zhang M., Ishii K., Hisaeda H., Murata S., Chiba T., Tanaka K., et al. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology 112 4 (2004) 567-574
32. Machado A.V., Cardoso J.E., Claser C., Rodrigues M.M., Gazzinelli R.T., and Bruna-Romero O. Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17 9 (2006) 898-908
33. +-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 73 9 (2005) 6017-6025
34. Atkinson E.A., and Bleackley R.C. Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol 15 3-4 (1995) 359-384
35. Trapani J.A., and Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2 10 (2002) 735-747
36. Rubio V., Stuge T.B., Singh N., Betts M.R., Weber J.S., Roederer M., et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9 11 (2003) 1377-1382
37. Santra S., Sun Y., Parvani J.G., Philippon V., Wyand M.S., Manson K., et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 81 16 (2007) 8563-8570
38. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 102 March (13) (2005) 4836-4841
39. Steensels M., Bublot M., Van Borm S., De Vriese J., Lambrecht B., Richard-Mazet A., et al. Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI. Vaccine 27 January (5) (2009) 646-654
40. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 May (7090) (2006) 239-243
41. Yoneyama Y., Ueda Y., Akutsu Y., Matsunaga A., Shimada H., Kato T., et al. Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells. Biochem Biophys Res Commun 355 March (1) (2007) 129-135
42. Yonemitsu Y., Kitson C., Ferrari S., Farley R., Griesenbach U., Judd D., et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18 9 (2000) 970-973
43. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 February (7028) (2005) 887-892
44. El-Sayed N.M., Myler P.J., Bartholomeu D.C., Nilsson D., Aggarwal G., Tran A.N., et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309 July (5733) (2005) 409-415
45. + T-cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2 8 (2006) e77
46. + cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun 74 4 (2006) 2477-2481
47. + T cells differentiation and proliferation by the timing of increase in the pathogen load. PLoS One 2 4 (2007) e393
48. + T cells leading to immunodominance. J Immunol 180 February (3) (2008) 1737-1748